Chelsea Counsel Co. Cuts Position in Sanofi $SNY

Chelsea Counsel Co. decreased its position in Sanofi (NASDAQ:SNY) by 86.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,910 shares of the company’s stock after selling 11,835 shares during the quarter. Chelsea Counsel Co.’s holdings in Sanofi were worth $93,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. AQR Capital Management LLC increased its position in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Sanofi by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares in the last quarter. Sivia Capital Partners LLC raised its stake in Sanofi by 5.4% during the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Sanofi by 36.1% during the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after purchasing an additional 875 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SNY. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Morgan Stanley set a $52.00 price target on Sanofi in a research report on Friday, May 1st. Finally, Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi Price Performance

Sanofi stock opened at $42.38 on Friday. Sanofi has a 12-month low of $41.85 and a 12-month high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average price of $44.79 and a 200-day moving average price of $46.33. The firm has a market capitalization of $102.75 billion, a PE ratio of 11.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.34.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were paid a $2.4225 dividend. The ex-dividend date of this dividend was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. Sanofi’s payout ratio is 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.